The U.S. Food and Drug Administration has formally notified healthcare providers of ongoing supply disruptions affecting stereotactic breast biopsy needles (FDA product code KNW), essential diagnostic instruments used in breast cancer screening and diagnosis. This supply shortage presents significant challenges for clinical operations across U.S. healthcare facilities, requiring immediate inventory assessment and contingency planning.
Stereotactic breast biopsy needles enable minimally invasive tissue sampling guided by three-dimensional imaging, allowing clinicians to differentiate benign from malignant breast lesions with precision. The shortage threatens to disrupt diagnostic pathways and delay patient care timelines. Healthcare organizations are advised to evaluate current inventory levels, establish alternative procurement strategies, and develop protocols to maintain continuity of breast diagnostic services during this period of device unavailability.
Read the full article on GMJ Newsroom.
Was this article helpful?
